Focus: Scynexis is a public biotech company focused on small-molecule antifungal therapies for infectious diseases and respiratory indications. The company is in clinical-stage development with a lean operating model.
Profile data last refreshed 18h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Scynexis to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Scynexis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Help build intelligence for Scynexis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
SCYNEXIS Appoints Sanjay Subramanian CFO as Biotech Advances Rare Disease Pipeline - citybiz
SCYNEXIS Appoints Sanjay Subramanian CFO as Biotech Advances Rare Disease Pipeline citybiz
A new finance chief brings 20 years of experience to SCYNEXIS - Stock Titan
A new finance chief brings 20 years of experience to SCYNEXIS Stock Titan
Scynexis: Q2 Earnings Snapshot - KTVB
Scynexis: Q2 Earnings Snapshot KTVB
8-K Filing: 60 DEGREES PHARMACEUTICALS, INC. (SXTP, SXTPW) (CIK 0001946563) — 60 DEGREES PHARMACEUTICALS, INC. INVESTOR PRESENTATION, DATED JULY 20, 2026
60 DEGREES PHARMACEUTICALS, INC. INVESTOR PRESENTATION, DATED JULY 20, 2026
SCYNEXIS (NASDAQ:SCYX) Is In A Strong Position To Grow Its Business - simplywall.st
SCYNEXIS (NASDAQ:SCYX) Is In A Strong Position To Grow Its Business simplywall.st
SCYNEXIS begins first human study of SCY-770 for rare kidney disease - Stock Titan
SCYNEXIS begins first human study of SCY-770 for rare kidney disease Stock Titan
Showing 6 of 7 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
A phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp to reduce the incidence of recurrent vulvovaginal candidiasis.
Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo